Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene

References

• Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006;194:S12-23
   PubMed Web of Science ®Google Scholar
• Dempster DW. Osteoporosis and the burden of osteoporosis-related fractures. Am J Manag Care 2011;17(Suppl 6):S164-9
   PubMedGoogle Scholar
• Inderjeeth CA, Foo AC, Lai MM, Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009;44:744-51
   PubMed Web of Science ®Google Scholar
• Vedantam R. Management of osteoporotic vertebral compression fractures: a review. Am J Clin Med 2009;6:14-18
   Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821-8
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• Pickar JH, Mirkin S. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Menopause Int 2010;16:121-8
   PubMedGoogle Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-38
   PubMed Web of Science ®Google Scholar
• Kanis J, Compston J, Cooper C, et al. The economic burden of fractures in the European Union in 2010 [abstract OC1]. Osteoporos Int 2012;23(Suppl 2):S57
   Google Scholar
• FRAX WHO Fracture Risk Assessment Tool. World Health Organization Collaborating Centre for Metabolic Bone Disease. Available at: http://www.shef.ac.uk/FRAX/ [Last accessed 28 October 2009]
   Google Scholar
• Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone 2009;44:734-43
   PubMed Web of Science ®Google Scholar
• Watts NB, Ettinger B, LeBoff MS. FRAX facts. J Bone Miner Res 2009;24:975-9
   PubMed Web of Science ®Google Scholar
• Prolia [package insert]. Thousand Oaks, CA: Amgen Inc., 2013
   Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-18
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Can Med Assoc J 2012;184:E431-4
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 2006;21:817-28
   PubMed Web of Science ®Google Scholar
• Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy – additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009;20:811-17
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012;27:1480-6
   PubMed Web of Science ®Google Scholar
• Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-55
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604
   PubMedGoogle Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7
   PubMed Web of Science ®Google Scholar
• Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (review). Cochrane Database Syst Rev 2008;(1):CD004523
   Google Scholar
• Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD001155
   Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223-31
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315-22
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22:373-90
   PubMed Web of Science ®Google Scholar
• Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 2012;23:2141-50
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
   PubMed Web of Science ®Google Scholar
• Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81
   PubMed Web of Science ®Google Scholar
• Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-36
   PubMed Web of Science ®Google Scholar
• Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012;27:687-93
   PubMed Web of Science ®Google Scholar
• Sutton EE, Riche DM. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012;46:1000-9
   PubMed Web of Science ®Google Scholar
• Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-9
   PubMed Web of Science ®Google Scholar
• McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999;10:301-11
   PubMed Web of Science ®Google Scholar
• Christiansen C, Chesnut CH, III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 2014;58:126-35
   PubMed Web of Science ®Google Scholar
• Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int 2012;23:797-809
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96:972-80
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-57
   PubMed Web of Science ®Google Scholar
• Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20
   PubMed Web of Science ®Google Scholar
• Boonen S, Black DM, Colon-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008;10:118-22
   PubMedGoogle Scholar
• Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk – a perspective. J Bone Miner Res 2012;27:963-74
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20:1663-73
   PubMed Web of Science ®Google Scholar
• Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009;94:2915-21
   PubMed Web of Science ®Google Scholar
• Neele SJ, Evertz R, De Valk-De RG, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9
   PubMed Web of Science ®Google Scholar
• Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-61
   PubMed Web of Science ®Google Scholar
• Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003;14:570-6
   PubMed Web of Science ®Google Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8:96-110
   PubMedGoogle Scholar
• Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009;122:S22-32
   PubMed Web of Science ®Google Scholar
• Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-4
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008;23:1435-41
   PubMed Web of Science ®Google Scholar
• Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011;22:741-53
   PubMed Web of Science ®Google Scholar
• Evista [package insert]. Indianapolis, IN: Eli Lilly and Company, 2011
   Google Scholar
• Ziller V, Wetzel K, Kyvernitakis I, et al. Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 2011;14:228-35
   PubMed Web of Science ®Google Scholar
• Guerri-Fernandez RC, Diez-Perez A. Is there a future for selective estrogen-receptor modulators in osteoporosis? Ther Adv Musculoskelet Dis 2012;4:55-9
   PubMedGoogle Scholar
• Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102-8
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-15
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-63
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567-76
   PubMed Web of Science ®Google Scholar
• Palacios S, de Villiers TJ, De Cicco-Nardone F, et al. Reproductive safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study [abstract S-7]. Menopause 2011;18:1344
   Web of Science ®Google Scholar
• Palacios S, Silverman S, Levine AB, et al. Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study [abstract 973]. International Menopause Society World Congress on Menopause; June 8–11 2011; Rome, Italy
   Google Scholar
• Bruyere O, Detilleux J, Chines A, Reginster JY. Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. Calcif Tissue Int 2012;91:244-9
   PubMed Web of Science ®Google Scholar
• Ellis A, Jansen J, Luo X, et al. Indirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of nonvertebral fractures in a high-risk postmenopausal osteoporosis population [abstract OC11]. Osteoporos Int 2012;23(Suppl 2):S64-5
   Google Scholar
• Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009;16:1193-6
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049-54
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Palacios S, Silverman S, et al. The effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX® [abstract P495]. Osteoporos Int 2012;23(Suppl 2):S278-9
   Google Scholar
• McCloskey E, Johansson H, Oden A, et al. Assessment of the effect of bazedoxifene on non-vertebral fracture risk [abstract FR0376]. J Bone Miner Res 2009;24(Suppl 1):S140
   Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729-35
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Adami S, Levine A, et al. The efficacy of bazedoxifene in postmenopausal women is independent from kidney function [abstract SU0441]. J Bone Miner Res 2011;26(Suppl 1):S368
   Google Scholar
• Adami S, Palacios S, Rizzoli R, et al. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 2013; epub ahead of print. DOI: 10.3109/13697137.2013.830605
   PubMed Web of Science ®Google Scholar
• Svedbom A, Luo X, Kanis J. Cost-effectiveness of bazedoxifene vs. raloxifene in the treatment of postmenopausal osteoporosis using FRAX® in European countries [abstract OC12]. Osteoporos Int 2012;23(Suppl 2):S65
   Google Scholar
• Hiligsmann M, Ben SW, Reginster JY. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res 2013;28:807-15
   PubMed Web of Science ®Google Scholar